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Abstract Photodynamic therapy (PDT) is a promising
treatment methodology whereby diseased cells and tissues
are destroyed by reactive oxygen species (ROS) by using a
combination of light and photosensitizers (PS). The medical
application of Rose Bengal (RB), photosensitizer with very
good ROS generation capability, is limited due to its
intrinsic toxicity and insufficient lipophilicity. In this report,
we evaluate the potential of polyamidoamine (PAMAM)
dendrimers in delivering RB and its phototoxic efficiency
towards a model cancer cell line. The spherical, nanoscaled
dendrimers could efficiently encapsulate RB and showed
characteristic spectral responses. The controlled release
property of dendrimer–RB formulation was clearly evident
from the in vitro drug release study. ROS generation was
confirmed in dendrimer–RB system upon white light
illumination. Photosensitization of Dalton’s Lymphoma
Ascite (DLA) cells incubated with dendrimer–RB formula-
tion caused remarkable photocytotoxicity. Importantly, the
use of dendrimer-based delivery system reduced the dark
toxicity of RB.
Keywords Photodynamic therapy . Dendrimer .
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1 Introduction
Photodynamic therapy is a method of clinical treatment
whereby diseased cells and tissues are destroyed by a
combination of light and special drugs called photosensi-
tizers (Lopez et al. 2010; Silva et al. 2009; Roy et al. 2003).
In addition, the presence of adequate molecular oxygen in
the tissue is also required. These components, tolerated
singly by the diseased cells, generate cytotoxic oxygen-
based molecular species when combined in proper dosage
and concentration (Robertson et al. 2009; Guo et al. 2010).
PDT is noninvasive and is recognized as a useful initial
treatment for malignant tumors (Dolmans et al. 2003;
Macdonald and Dougherty 2001). PDT using porfimer
sodium (Photofrin®) has been approved for the treatment of
esophageal cancer in the United States and Canada, early
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and late stage lung cancers in the Netherlands, bladder
cancer in Canada, and early stage lung, esophageal, gastric
and cervical cancers in Japan (Fisher et al. 1996). Photo-
sensitizers can be divided into hydrophilic and hydrophobic
compounds. The major drawbacks of the hydrophobic
photosensitizers are that they cannot be simply injected
intravenously since they form aggregates in solution that
restricts their medical applications (Orenstein et al. 1996;
Labouebe et al. 2006). Hence, hydrophobic photosensitizers
need complex formulation for systematic delivery (Fenga et
al. 2004; Shive and Anderson 1997). Hydrophilic photo-
sensitizers are advantageous than hydrophobic photosensi-
tizers since they can be easily delivered intravenously and
significantly improve tumor killing (Moore et al. 2009;
Vrouenraets et al. 2002). However, hydrophilic photo-
sensitizers poorly accumulate in tumor cells as it finds
difficulty in crossing cell membranes. This is mainly
because the cellular transport systems in cancer cells are
slowly accelerated for hydrophilic drugs to pass through
when compared to normal cells (Kessel 1981).
Rose Bengal (RB) is a hydrophilic photosensitizer with a
high absorption coefficient in the visible region of the
spectrum at 552 nm showing good quantum yield of singlet
oxygen (Kochevar et al. 1996). Although it has potential in
photodynamic therapy of tumors, its tendency to aggregate
in solution under physiological condition decreases the yield
of reactive oxygen species (ROS) (Killig et al. 2004).
Therefore, it is essential to have an appropriate formulation
for the delivery of this hydrophilic photosensitizer in
therapeutic levels. The ideal drug delivery system for carrying
PDT should be biodegradable, have minimum toxicity,
incorporate the photosensitizer without loss or alteration of
the sensitizer activity and provide an environment where the
photosensitizer can be administered in monomeric form
(Konan et al. 2002). Importantly, the delivery system should
enable selective accumulation of the PS within the diseased
tissue in therapeutic concentrations with little or no uptake
by nontarget cells (Chatterjee et al. 2008).
It is expected that charged or slightly lipophilic nano-
scaled drug delivery systems can be used for efficient
delivery of highly hydrophilic photosensitizers for PDT of
cancer. In this regard, the use of dendrimer-based nano-
carriers is a promising method for the tumor specific
delivery of PS. Nanoparticles, such as nanospheres and
nanocapsules, possess high impact in delivery system as PS
carriers because they can meet all the requirements for an
ideal PDT agent (Premanathan et al. 2011; Murday et al.
2009; Koo et al. 2005). Dendrimers can be considered as
the most versatile, compositionally and structurally con-
trolled synthetic nanoscale building blocks available today
(Koda et al. 2008; Bechet et al. 2008). Dendrimers have
high degree of molecular uniformity, loading capacity,
biocompatibility and a highly functionalized terminal
surface that facilitates modification of the solubility of
drugs to help target the drug to its therapeutic sites, or to
alter the release profile of the therapeutic agent (Svenson
and Tomalia 2005; Jansen et al. 1994). With the aim of
improving the drug delivery and release kinetics suitable
for carrying PDT and diminishing the dark toxicity of RB,
dendrimer-based delivery system could be a better choice.
The present study relies on polyamidoamine (PAMAM)
dendritic nanostructures as an efficient drug delivery system
for a well-known hydrophilic photosensitizer, Rose Bengal
that was evaluated by investigating the interaction between
the dendrimer and RB and the photodynamic efficacy.
However, our studies explored the influence of G2.5
PAMAM+RB on Dalton’s Lymphoma Ascite (DLA) cancer
cell lines. A potential application of PAMAMdendrimers as an
efficient drug delivery system for a hydrophilic photosensitizer
will provide new opportunities in nanomedicine for PDT of
cancer.
2 Material and methods
2.1 Materials
Methanol was obtained from Spectrum Chemicals, India.
Methyl acrylate was procured from Loba Chemicals, India.
Ethylenediamine, ammonium molybdate, pyridine and
diethyl ether were obtained from Merck, India. Ammonia
and potassium iodide were obtained from SD Fine
Chemicals, India. Rose Bengal was purchased from
Aldrich, USA. Dialysis tubing (12–14 kDa cutoff size)
was obtained from Himedia, India. All the chemicals were
used as received except methanol, which was distilled twice
before use.
2.2 Synthesis of PAMAM dendrimer
PAMAM dendrimers with various generations have been
synthesized using a divergent method. The synthesis of
PAMAM dendrimers undergoes Michael addition reaction
(Hedden and Bauer 2003). Ammonia and 100 equiv. of
methylacrylate (MA) were dissolved in methanol, respectively.
Ammonia solution was added to MA solution dropwise.
Reactionmixture was stirred in 37°C for 2 days. After reaction,
solvent was removed by a rotary evaporator and residual
product was stored in vacuum.
NH3 þ 3CH2CHCOOCH3!37
C for 48 hrs N CH2CH2COOCH3ð Þ3
ðG0:5Þ
PAMAM G 0.5 and 100 equiv. of ethylenediamine
(EDA) was dissolved in methanol, respectively. PAMAM
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solution was added to EDA solution and stirred at 50°C for
2 days. After reaction was completed, solvent was removed
using a rotary evaporator. Residual product was precipitated
in ethyl ether two times and stored in vacuum.
N CH2CH2COOCH3ð Þ þ 3NH2CH2NH2 !50
C48 hrs N CH2CH2CONHCH2CH2NH2ð Þ3 þ 3CH3OH ðG1:0Þ
The first generation dendrimer G1.0 was purified by three
times centrifugation and redispersion in methanol. Addition of
MA in proper molar ratios with G1.0 under heating (50°C) for
48 h results in production of G1.5 PAMAM dendrimer.
Subsequent addition of EDA generates G2.0 dendrimer.
Likewise, the chain reaction is continued till the synthesis
for G2.5 dendrimer. The dendrimer was purified at each step
by centrifugation for 30 min at 16,000g and resuspending in
methanol solution. Finally, the dendrimer solution was
dialyzed against methanol water (1:10) mixture for 24 h in
order to remove any nonreacted chemical species.
2.3 Encapsulation of Rose Bengal into the PAMAM
dendritic box
The G2.5 PAMAMdendrimer and RBwere mixed in the ratio
of 10:1 in a solution of 20 ml of methanol and 5 ml of water.
The resulting solution was vigorously stirred at 500 rpm for
24 h using a magnetic stirrer. After 24 h, the solvent was
removed under vacuum using a rotary evaporator. The final
product obtained was purified by centrifugation at 16,000g
for 30 min followed by dialysis and stored at 4°C.
2.4 Characterization techniques
Surface morphology of G2.5 PAMAM dendrimer was
analyzed using atomic force microscopy (AFM) in contact
mode using XE 70, SPM, Park System, South Korea, in a scan
area of 20 μm. The sample preparation was performed by
taking 5 μl of G2.5 PAMAM and diluting 100 times. The zeta
potential analysis was performed at 25°C, in MilliQ® water
using Zetasizer Nano, Malvern Instruments, UK. A few drops
of the prepared solution were allowed to spin coat on a glass
substrate for 10 min and then dried before measurement. UV–
vis spectra (Lambda 25, Perkin Elmer, USA) of PAMAM
dendrimers were measured in methanol:water (50% v/v).
Fourier transform infrared (FTIR) spectra of the samples
were recorded in liquid mode using a modern Bruker optic
GmbH-Alpha T spectrometer, Germany. Fluorescence spectra
of were obtained in aqueous environment using a spectro-
flourimeter (Jasco FP-6300, Japan).
2.5 Estimation of drug loading and encapsulation efficiency
The amount of drug loaded into the dendrimer and the
encapsulation efficiency of the G2.5 PAMAM dendrimers
were measured spectrophotometrically, using the formulas
given below:
Drug loading %ð Þ ¼ W1 W2=½   100 ð1Þ
Encapsulation efficiency ¼ W3 W4ð Þ W4=½   100 ð2Þ
where
W1 weight of the drug present in dendrimer
W2 net weight of the dendrimer
W3 weight of the drug added, and
W4 weight of the drug released into the supernatant.
2.6 Measurement of drug release kinetics
The release of RB from the G2.5 PAMAM was measured
spectrophotometrically as follows: 50 mg of RB encapsulated
dendrimer was made up to 1 ml using a mixture of methanol:
water (50:50, v/v). This solution was dialyzed using a dialysis
tubing with a MW cutoff 12,000–14,000 Da (~2.4 nm)
(Himedia, India) against phosphate buffer saline (PBS) of pH
7.4 at 37°C with mild stirring. This was continued for 72 h
and at each time interval 1 ml was withdrawn from the PBS
for spectrophotometric analysis at λmax 540 nm and was
replaced by fresh PBS of the same amount. A graph was
plotted with cumulative release% against time interval in
hours representing the drug release profile.
2.7 Light source for PDT
A 150 W xenon arc lamp was used as a light source. The
therapeutic window was adjusted by using 10% KI (5 cm
path length) and pyridine (1 cm path length) as a filter for
UV radiation. The specimen was kept in an open quartz
cuvette and air saturated by magnetic stirring. It was
irradiated at a distance of 12 cm from the light source.
2.8 Measurement of quantum yield of ROS generation
by iodide method
The iodide assay was used for the evaluation of ROS
generation of RB encapsulated G2.5 PAMAM dendrimers
(Mosinger and Micka 1997). This assay is based on the
reaction of singlet oxygen (1O2) (produced in the photody-
namic reaction) with I− in the presence of ammonium
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molybdate as a catalyst. The reaction product is I3
−, the
amount of which (measured spectrophotometrically at λ=
351 nm) is directly proportional to the generated 1O2.
2.9 In vitro cell viability test—MTT assay
For MTT cell viability assay, 2.5×104 DLA cells per well
were seeded onto a well of 96-well plates in RPMI 1640
media for 2 h incubation, treated with various concen-
trations of RB in free and dendrimer encapsulated form
and photoirradiated for 10 min using a xenon arc lamp.
The media was changed to fresh RPMI 1640 media with
10% PBS and incubated for 12 h. Then, 5 mg/ml MTT
solution (20 μl/well) was added to each well, and cells
were incubated for an additional 4 h at 37°C. The
supernatant was aspirated and 100 μl of isopropanol was
added to the wells to dissolve any blue precipitate present.
The absorbance was then measured at 570 nm by a
microplate reader. Cell viability was calculated using the
following formula:
Cell viability ¼ Average absorbance of treated group Average absorbance of the control group=ð Þ  100 ð3Þ
3 Results and discussion
3.1 Synthesis and characterization of PAMAM dendrimers
The PAMAM dendrimers of various generations (G0.5,
G1.0, G1.5, G2.0 and G2.5) are synthesized using the
Michael addition method as described in the previous
section. The PAMAM dendrimers with ammonia as the core
molecule possess an ester group (R-COO-R) and amine (R-
CO-NH2) group as terminal surfaces in the successive half
and full generation. The various generation dendrimers
were characterized by UV–vis spectroscopy, FTIR spec-
troscopy, AFM and zeta potential. The UV–vis spectrosco-
py of all generations of PAMAM dendrimers shows a
characteristic absorption at 275 to 290 nm (Figure S1). The
FTIR spectra of the half generation (G0.5/G1.5/G2.5)
shows a characteristic –C=O stretching vibrations around
1,729 cm−1 due to the presence of a free ester (C=O) group
in the end surface (Kolhe et al. 2003). In addition to this, a
band at 1,000 cm−1 to 1,200 cm−1 also appeared, which is
assigned to the –C–O stretching mode [Fig. 3, 2.5
PAMAM]. The FTIR spectrum of the full generation
dendrimers shows characteristic N–H stretching vibrations
around 1,620–1,650 cm−1 because of the reaction of ester
with amine making it as an amine end (Figure S2).
From the zeta potential values of various generations, it
is possible to evaluate the nature of the surface groups
present in the dendrimers (Tomalia et al. 2007). The half
generation PAMAM dendrimers are electrically neutral and
show positive potential values. The full generation
PAMAM dendrimers are electronegative and they possess
negative potential values. The zeta potential data also
confirmed the presence of the charged/neutral terminals at
the surfaces. The zeta potential values of all the PAMAM
dendrimers of various generations are given in Table 1. The
AFM images of the 2.5 G PAMAM dendrimer (2D and 3D)
recorded in noncontact mode is given as Fig. 1(a) and (b)
respectively. From the image, it is clear that most of the
Fig. 1 Surface morphology of G2.5 PAMAM dendrimer measured using AFM
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particles appeared spherical in shape with particle size
around 20 nm.
3.2 Dendrimer–Rose Bengal interaction
The dendritic cavity present in the dendrimer molecules
enables them to hold the guest molecule (drug). Such host–
guest interactions can be successfully followed spectropho-
tometrically. UV–visible absorption peak of G2.5 den-
drimer and the RB drug in methanol is shown as in
Fig. 2. The dendrimer shows an absorption band in the UV
region around 270–280 nm and the free RB shows a peak at
552 nm (Fig. 2) (Fini et al. 2007). A weak band appearing
around 500 nm is a measure of aggregation of the RB
molecules in solution (Xu and Neckers 1989). On mixing
equimolar amounts of dendrimer and the drug, the band
appearing in the visible region (around 552 nm) is shifted
towards 545 nm. Because of the movement of drug
molecules into the dendritic entity, noncovalent interactions
between the RB and the internal cavities of PAMAM
dendrimers make such a blue shift (Cheng et al. 2007). In
addition to this, intermolecular interaction between the
carboxyl group of RB and the terminal groups of PAMAM
dendrimers also makes such blue shift (Gigimol and
Mathew 2007). In the UV–vis spectra of the G2.5
PAMAM+RB, there is no observation of broad shoulder
peak around 500 nm since on encapsulation, the delocal-
ization of the lone pair of electrons present in the RB
molecule with dendrimer (Finia et al. 2004). These results
concluded that the RB molecules interact well with G2.5
PAMAM dendrimers through cavity encapsulation.
FTIR spectroscopy is also used to study the host–guest
interactions. The FTIR spectra of G2.5 PAMAM dendrimer,
free RB and the G2.5 PAMAM+RB are shown in Fig. 3.
The FTIR of G2.5 PAMAM dendrimer shows characteristic
C=O stretching vibrations around 1,729 cm−1 that is
assigned to an ester group (present as free terminal group
in G2.5 dendrimer). The band at 1,641 cm−1 is assigned to
N–H deformation vibration present in the amide group
(Kolhe et al. 2003). In addition to this, a 1,000 cm−1 to
1,200 cm−1 band is assigned to the C–O stretching mode.
Peaks in the region 2,800–3,200 cm−1 corresponds to N–H
stretching and C–H stretching vibrations (Devarakonda et
al. 2007). The FTIR spectra of RB shows a characteristic
C=O stretching at 1,620 cm−1 (Jhonsi et al. 2009). All the
bands were found individually on the dendrimer and the
drug shifts if both are mixed together. The C=O and N–H
deformation bands shifted to lower frequencies 1,718 cm−1
and 1,540 cm−1 that could be explained by intermolecular
hydrogen bonding between electronegative atoms in the RB
with the G2.5 PAMAM dendrimer. These observations
reveal that the RB molecules are encapsulated in the
dendritic box through their carboxyl group via electrostatic
interaction.
Further, the interaction between RB and PAMAM
dendrimer was also studied by fluorescence quenching
measurements. Figure 4 represents the effect of PAMAM
dendrimer on the fluorescence spectra of RB. The G2.5
PAMAM+RB showed decreased emission intensity, com-
pared to free RB. Further, there is no band shift in the
spectra of dendrimer–RB complex compared to free RB,
indicating that no structural change occurred. The quench-
ing observed is due to the electronegative carboxyl group of
RB, which increased the interaction of dye with the
dendrimer (Jhonsi et al. 2009). Zeta potential measurements
enable the understanding of the interaction of RB and
dendrimer moieties. G2.5 PAMAM dendrimer possesses a
surface charge of +0.168 mV. Upon interaction with RB the
surface charge of the dendrimer changed to −1.33 mV. This
may be due to the presence of surface attached RB
molecules that are having more electronegative chlorine
Fig. 3 FTIR spectra of G2.5 PAMAM dendrimer, free RB and G2.5
PAMAM+RB
Fig. 2 UV–vis spectra of G2.5 PAMAM dendrimer, free RB and G2.5
PAMAM+RB
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atoms and a keto group in the molecule. Hence, the above
characterization techniques reveal that the RB molecules
are encapsulated in the dendritic cavity and also some of
the RB molecules are absorbed at the terminal surface of
the PAMAM dendrimers.
3.3 Drug loading and encapsulation efficiency of G2.5
PAMAM+RB nanocapsules
High drug loading and better encapsulation efficiency is
expected for an ideal drug delivery agent, thereby, reducing
the quantity of the matrix materials for drug administration
(Mohanraj and Chen 2006). The drug loading in the G2.5
PAMAM+RB is through the absorption technique. Hence,
the delivery system should be ideal in case of drug loading
efficiency and drug release kinetics for carrying PDT, not
suppressing the quantum yield of the PS after encapsula-
tion. The amount of drug loaded into the dendrimer and the
encapsulation efficiency of the G2.5 PAMAM dendrimers
were measured spectrophotometrically during purification
of G2.5 PAMAM+RB by centrifugation and are to be
observed as 1.8% and 92.5% respectively.
3.4 In vitro drug release kinetics of G2.5 PAMAM+RB
In our G2.5 PAMAM+RB, the RB molecules are physically
encapsulated in the cavity of the PAMAM dendrimer and a
minimum quantity is absorbed at the terminal surface. The
possible drug release kinetics is through diffusion process
(Kedar et al. 2010). Figure 5 shows the in vitro drug release
profile of the RB encapsulated G2.5 PAMAM dendrimers
followed spectrophotometrically for a period of 72 h. It is
observed that the systematic release of RB after 12, 24 and
48 h are 35%, 50% and 74% respectively. After 72 h, 83%
of drug release is noticed. From the graph, it is clear that the
rate of release of RB from the dendrimer at the initial stage
is high whereas on the final stage it is found as low. The
quicker release in the initial hours is the release of small
amount of RB attached to the surface groups of the
dendrimer. The drug release becomes somewhat slower, i.e.,
after 12 h is probably due to the encapsulated drug that is
present in the dendritic cavity or the inner core of PAMAM.
Sustained release was noticed after 48 h. The drug release
studies shows that G2.5 PAMAM dendritic system possesses
excellent controlled release properties suitable for carrying
PDT of hydrophilic photosensitizers.
3.5 ROS quantum efficiency of G2.5 PAMAM+RB
The significant factor influencing the PDT efficiency is the
quantum yield of ROS generation from the PS. The ROS
generation of free RB and its encapsulated form was
evaluated by determining the quantum yield by iodide
method. It is experimentally found that the 1O2 quantum
yield for free RB is 0.76. The 1O2 quantum yield for G2.5
PAMAM+RB was measured as 0.71 from using the iodide
method (Mosinger and Micka 1997). Figure 6 depicts the
graphical representation of the change in absorbance of the
iodide band (351 nm) against the irradiation time for
variously concentrated solutions of RB encapsulated in
G2.5 PAMAM dendrimers. It is clear from Fig. 6. that the
Fig. 5 RB release kinetics from the G2.5 PAMAM+RB
Fig. 4 Fluorescence spectra of free RB and G2.5 PAMAM+RB
Fig. 6 Estimation of quantum yield of ROS generation from the
nanocapsules by the iodide method. Graph shows the change in
absorbance of the iodide band (351 nm) against the irradiation time for
variously concentrated solutions of RB encapsulated in G2.5 PAMAM
dendrimers
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absorption of the iodide band increases with the increase in
the concentration of the G2.5 PAMAM+RB, which
indirectly show the increase in the ROS generation of
G2.5 PAMAM+RB at higher concentration. These results
strongly demonstrate that the G2.5 PAMAM can be an ideal
drug delivery agent since no such alteration in the ROS activity
is noticed when compared to the activity of the free RB.
3.6 Phototoxicity and dark toxicity of G2.5 PAMAM+RB
The aim was to investigate the photosensitizing activity of
G2.5 PAMAM+RB against DLA cells and its efficiency as
a potential PDT treatment for cancer. The cell viability of
DLA cells upon photoirradiation as a function of concen-
tration of G2.5 PAMAM+RB indicates the photodynamic
effect in vitro. Figure 7 illustrates the photodynamic effect
on the DLA cell line, as a function of the photosensitizer
concentration. The free RB produced the lower photody-
namic effect when compared to G2.5PAMAM+RB. The
beneficial effect of the RB loaded dendrimers was mainly
highlighted at a RB concentration of 510 nM. When the
doses of the free RB and the G2.5 PAMAM+RB are
increased to 510 nM, it was found that the cell viability
percentage for G2.5 PAMAM+RB-treated cells was 24.9%
when compared to the 38% cell viability for free RB-treated
cells. The phototoxicity results show that the G2.5
PAMAM+RB are more toxic to the DLA cells compared
to the toxicity of free RB. PAMAM dendrimer is a
hyperbranched molecule and the amount of drug loading
is as low as 1.8%, which ensures the uniform distribution of
the photosensitizer in the dendritic matrix and this enables
sustained drug release kinetics suitable for carrying PDT.
Low dark toxicity is one of the significant criteria for
assessing the usefulness of photosensitizers, since the major
side effects in clinical PDT result from the dark toxicity of
photosensitizer to normal tissue. From Fig. 8, at lower
concentration of the free RB, the cell viability is 92% and
an increase in concentration of the free RB to 510 nM
makes it more toxic and the cell viability is reduced to 56%.
The dark toxicity of the RB-loaded dendritic nanostructures
exhibits nontoxic at lower concentrations and is less toxic at
higher concentrations (the cell viability is 69.8% at
510 nM) as compared to the dark toxicity of free RB. The
very low toxicity of G2.5 PAMAM+RB might result from
the good biocompatibility and low toxicity of PAMAM
dendrimers (Koda et al. 2008; Bechet et al. 2008; Svenson
and Tomalia 2005). It can be highlighted that differential
toxicity was observed for G2.5 PAMAM+RB in the
presence and absence of light against cancer cells.
Therefore, the efficient photodynamic efficacy of G2.5
PAMAM+RB, together with the above-mentioned advan-
tages, makes this type of formulation for delivery of
photosensitizer in PDT potentially very useful for clinical
application.
4 Conclusion
PAMAM dendritic nanostructures could effectively deliver
RB photosensitizers into cancer cells and produce enhanced
photodynamic efficacy. The interaction between the
PAMAM dendrimer and RB are investigated by UV–vis
and FTIR spectra, fluorescence quenching and zeta poten-
tial measurements. Our systemic investigation of the
dendrimer-based formulation of RB shows that it is feasible
to encapsulate even a hydrophilic photosensitizer with
excellent encapsulation efficiency and release kinetics.
Results showed that drug release was quite faster in the
initial hours and, above 80%, was released in 72 h, which
was found to be more satisfactory for a water-soluble
photosensitizer. It is observed that the PAMAM dendrimer-
based delivery of RB could retain its ROS generation
property upon irradiation and also could reduce its toxicity
by holding the RB molecules in the internal cavities.
Fig. 8 Dark toxicity of free RB and G2.5 PAMAM+RB
Fig. 7 Phototoxicity of free RB and G2.5 PAMAM+RB
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Importantly, the dendritic formulation exhibited minimized
dark toxicity within the concentration used and enhanced
phototoxicity to DLA cells compared to the dark phototoxicity
of free RB. The key findings of our work with the above-
mentioned advantages ensure that PAMAM dendrimer-based
nanocarriers of PS delivery should be a promising candidate
for PDT.
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